about
The next generation of positron emission tomography radiopharmaceuticals in oncology.Synthesis and evaluation of (18)F-labeled ATP competitive inhibitors of topoisomerase II as probes for imaging topoisomerase II expression.BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib.Efficient (18)F-labeling of large 37-amino-acid pHLIP peptide analogues and their biological evaluation.Design, synthesis and in vitro drug release investigation of new potential 5-FU prodrugs.Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines.Development and validation of a high-performance liquid chromatography method for the quantitation of intracellular PARP inhibitor Olaparib in cancer cells.The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell LinesLow-Dose and Long-Term Olaparib Treatment Sensitizes MDA-MB-231 and SUM1315 Triple-Negative Breast Cancers Spheroids to Fractioned Radiotherapy
P50
Q35525690-22A13ABC-67D5-4AEA-BFAD-C6971E9A7DF2Q35525919-D43B1077-6BCE-4FC8-A385-3A88885EFB04Q35909731-696047D8-0111-4EB9-9545-CEF9EA68B2CDQ39316483-14542B40-45E9-4E85-91BE-8C6712EF1E78Q39550994-B2230007-CEF6-4730-9015-458EE9F12CA1Q47164952-1157213D-DE68-441E-8AD3-F73D178C8736Q50136529-36E12DA3-2A7A-46C1-AD25-FD1817E6E89BQ64066030-2D4B68A8-A493-4CA4-A7A9-147F9C4224C1Q92326798-ED026E43-EC96-4538-825C-4D0C72E5B335
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Pierre Daumar
@en
Pierre Daumar
@nl
type
label
Pierre Daumar
@en
Pierre Daumar
@nl
prefLabel
Pierre Daumar
@en
Pierre Daumar
@nl
P31
P496
0000-0003-0386-7171